Deciphera Pharmaceuticals (DCPH) 30 Oct 232023 Q3 Earnings call transcript

Good morning, everyone, and welcome to the Deciphera Pharmaceuticals MOTION Top Line Data and Third Quarter 2023 Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Jen Larson, Senior Vice President of Finance and Investor Relations. Jen?

Thank you, operator. all us you thank and for today. joining Welcome, President and Investor Jen Larson, Finance Vice Senior I'm Relations. of general statements pursuant and remind me we Financial Chief of With we I this provide Hoerter, results you our Officer.Before Officer; Chief Chief Reform that Head Executive Martin, morning Vimseltinib are Officer; a that President XXXX. to Matt to not of forward-looking any safe Act and on Tucker the data facts Kelly, our Duarte, to Litigation Chief provisions are make and quarter would begin, Commercial Private call to International; third this are like Margarida corporate Securities and Steve harbor of the historical update statements Medical the Sherman, made discuss Dan financial Officer; preclinical Examples of commercialization and Vimseltinib, our of include expectations clinical programs, including our and corporate guidance. QINLOCK our

could materially by Forward-looking statements, our uncertainties substantial results assure you be that and expectations implied or actual expressed those or that will differ statements achieved. risks the forth statements. we Such filings. uncertainties those cannot include cause to assume and SEC involve forward-looking our as to quarterly well Form forward-looking set risks as other recent in our obligation We no revise report and any on update most XX-Q from

Chief now a of will Officer will over call, the turn company's President Executive I be replay that, call and this Steve website, Following available on Deciphera. www.deciphera.com.With the to Steve? Hoerter,

profile. sales. we Phase This as compelling X in data from The the host you, TGCT top results the MOTION updated that QINLOCK was results, morning's third MOTION review from you morning, the our joining as Phase call exceptional Thank for X/X Vimseltinib us today.We're morning, good this well study announced record thrilled to Jen, financial has measures patient-reported Vimseltinib quarter announced all and Thank study Vimseltinib offer showcasing everyone. benefits key today the we a clinical clinical line with of safety who primary a study. profile also to the of substantial pivotal to earlier that unmet totality a condition debilitating with secondary medical across we an a TGCT people endpoints exceptional offers suffer and showing achieving needs. favorable the believe from and chronic outcomes Based its of significant patients potential Vimseltinib TGCT, on resounding for success, to range data, wide

the Head for I'll studies, data and clinical we DCC-XXXX, about commitment file hand are generate our a Margarida hard the dedication and TGCT. inhibitor in then the to treating resilience in we this of based next strong care Matt. over line another file candidates a X the moment last discuss we around their with to participated Vimseltinib GIST as submit QINLOCK's combination our Officer, is the the to focused study $X caregivers teams benefit to result quarter years. advancing to deliver look time and more over today International, our addition, EU study have increasing and multiple treatment fourth also of and performance of share later investigators, Commercial are potential, and Duarte, to We're revenue peak performance novel on of work turn to earlier around excited XX% access standard extending from for over of professionals potential potential X/X in our being to QX a regulatory now U.S. year. the generate to Vimseltinib thousands in driving an XX% follow-up, a longest more the in forward over report of the as the very we validate wide inhibitor studied range X the unpromoted periods pipeline much call the of and benefits families. of inhibitor, Phase and year believe U.S. the quarter-over-quarter. and X data announced pan-RAF the best-in-class cancers.Before first-in-class updated details have new DCC-XXXX, the second Vimseltinib also median for grateful in Dan We our and treatment Meanwhile, it track who journey will QINLOCK another first on year to of world next QINLOCK's international quarter in as cohorts Martin, the the NDA of product a remain approach seek also of MAA healthcare our execution we strong to quarters, to even of Sherman business QINLOCK, we Phase year-over-year for us billion inspired authorities program.With have these Bolstering QINLOCK DCC-XXXX, first-in-class Together, an revenue. deep patients half treatment and in are now participated I'd treatment to along MOTION on than of which expect view in development self-sustaining will our approximately who quarter, thank deliver prepare Matt X/X company. for to IND to record we net and commercial for biotechnology thereafter.Today with shortly see can pan-KIT Their patients potential our patient world.We the global our in for I to to study as with in ULK represents highlighting the a QINLOCK discuss TGCT step fully the that, on with longer like take to After patients. with focused in integrated, increased to IND almost results, use duration engaging well physician significant greater In for continued the factors on the decision. that our patients expanding of Chief product years, potential to lines become proof-of-concept

stiffness with inhibit Steve. potential the become Vimseltinib inhibitor safety we If been in Thanks, CSFX profile. the chronic based independently. and on are the an Patients their typically to and of XXs a very diagnosed without favorable ability medical TGCT effective an XXs severe significant which ability to or that a we create to in of control loss and unmet today. TGCT in all selectively patients' can standard address limit therapy effective or to the be potently expected a TGCT of work care difficult can has a announced receptor with to a of function lives, switch pain, results normal to with quality healthy their activities including swelling, TGCT mobility, Vimseltinib a we've approved, XXs, are believe daily active, normal condition and have is TGCT associated life. profound lead needs and oral impact kinase the severely lifespan, have treatments, to positive continue on their but diagnosis developing to can designed

their pharmaceutical recur Those to initial treatment medications some to pain While surgical surgery patients standard or morbidity. their subsequent treatments, may curative not their treat are receive variety patients resection surgeries. is after a of for a significant many, steroids amenable disease including or and and

typically later, receptor only which a imatinib, agent, inhibitor to CSFX the challenging hepatotoxicity weak important with discuss has in will a is either Pexidartinib not and the but which that note other are due an off-label effective patients that black specific side approved is CSFX REMS and pexidartinib. serious will inhibitors program. a box in receptor the It's safety to warning Dan believed effects As have seen off-target pexidartinib, be to or TKI, profile some cholestatic to is the receive resulted U.S. U.S. it therapy also in these a been

randomized profile, U.S. for study unmet to the not need see study EMA that at to risk-benefit study XX pexidartinib. with measured X-part blinded compared surgery. approve XX double-blind, to the radiologic safety The objective safe assessed its people review or lives of placebo-controlled is assess placebo. drug TGCT.The world well-tolerated twice a We can and of of rate Given nonamenable help and patients by randomized, Vimseltinib is of the to receive efficacy week by milligrams weekly were placebo. as primary independent the endpoint X:X and TGCT around in medical a RECIST MOTION the in either a improve response Vimseltinib did with and large XXX the patients

top important made review starting of and the in and role on will Today, patients that feel an In endpoints and addition to efficacy how play how are key for line ORR, These special treatment therapy. MOTION patients' evaluated X we overall study. a from are Part picture. in function number results of staying of interest the TKI measures in decisions the incredibly part of secondary the

X/X most have of and patients arms second with study been receive had efficacy an which being the the X have and part from demographics treated the disease systemic promotion The years patients patients the were study are majority and approximately part to X longer-term previously updated common as as expected the and A period the present median surgery treatment a Vimseltinib. of of patients therapy. disease baseline We'll the in location MOTION of age with least knee. prior XX had open-label able TKI safety with results diffuse is of matures.The at in on both

rate statistically at than Vimseltinib significant of primary and that XX less week X based was report compared the to placebo. on placebo a the excited response arm to clinically with endpoint, meaningful to are We compared The its in for XX% MOTION ORR X.XXXX. for IRR improvement p-value demonstrating met

active a XX% and patients increase and response. endpoints, of showed A, have result, pleased that can by score improvement at with tumor demonstrating measuring as asymmetric X-fold has can an placebo week patients' range here improvement X% very be an of study placebo. Vimseltinib We consistent significant increase score, data past with TGCT we range a Treatment life key of endpoints, week motion of to as of disclosed a cut due response active volume the were Vimseltinib of all rate the of its improvement a at an will approximately over and provides and placebo. Measuring key today.Vimseltinib irregular in pain first XX% in to showed in motion, XX% worst improvement results sector expect for as function, TGCT also volume remain is the were become to X.X%. in the RECIST And highly a of meaningful while to RECIST X quality that placebo. Phase showed rate statistically the clinically of Success impact patients growth. response. rate XX.X%, including range response from motion, stiffness, important significant compared Vimseltinib method shown rate week score with These response we response X XX recent on volume with response tumor compared tumor with time Cohort XX% to shape most secondary XX, significant physical study challenging compared

X/X is were always important a to or adverse TGCT of event.In choice the in mostly macrophage clear have cholestatic adverse top study, into MOTION or line provides this of we are would of well patients results grade Phase seems increased not X% continues positive the an advantage cells arm the remember MOTION was order physicians the Only of a about due potent when resulting patients liver consistent in can in effects MOTION presented in levels. FCB to important to which study, a treatment of the use to treatment as window we hepatotoxicity share continue that therapy also along that known [indiscernible] inhibition common in week. levels These in decisions the for become think these Vimseltinib reported enzymes In not is from pexidartinib, of study X the serum the treatment their that X/X making and receptor CSFX previously distinct exposure. treatment XX, annual in with We results to a CSFX and treat emergent only inhibitors. the Kupffer well it profile consistent data important, strong later of we increased X to FC more even to delivered in also in studies. grade and essential It Phase This are enzymes tolerated week increase how favorable the have with excited updated most the X event be safety how the was safety known Vimseltinib CPK. to disease.The addition competitive The observation only X% to from with will well-tolerated systemic disclosed at serum but be with Vimseltinib with CTOS long-term X. were are to patients be the provide are the meeting profile events patients. being with Vimseltinib whether discontinued treatment-emergent after than Dublin improve that results receptor seen strong

reached longest This Building of X data TGCT June approaching enrollment duration with to ORR the our is after XX of in patients. years. increasing as X the across clinical patients XX.X Since Cohort Phase date, continue enrolled XX% Phase across the to months B. antitumor increasing over median median A and Cohort X cohorts, and encouraging to in completed line data duration of time, of regardless continued XX% observed demonstrate the still these increase and cohorts. the duration encouraging treatment to therapy with of longest in receptor this results on X we of Phase months X X and nearly the cutoff, is prior patient X response enrolled time its In Phase durable rates an duration As Vimseltinib response increased Phase B. upon in the been cutoff lives activity data X, have XX% CSFX complement response therapy benefit potential and Phase the update X now the Phase had the for make in a we all over and of across demonstrating data treatment the with to not A, profile cut, cut, efficacy of efficacy in prior years. Phase difference XX to top Cohort Cohort fully And of all and cohorts the X best in MOTION important Vimseltinib's X cohorts. XX

A patients patients Phase study. of on XX% XX% remained X Cohort and Importantly, of

X/X announced treatment We highlight well treatment the profile the of the Consistent long-term treatment-emergent the expect Phase analysis adverse safety that the In to the tolerated we study, only pooled Vimseltinib of patients XX average MOTION, study X% with discontinued exposure. continue matures.Finally, due risk-benefit to increase favorable data events. Vimseltinib. will duration from patients with as the continues to today longer-term remained of

study that combined is believe to MOTION We the X/X and Vimseltinib secondary offers truly how for. from key been their impactful data can primary the an treatment results Phase have we endpoints way the are time. believe waiting that have and X exceptional profile all be of TGCT safety over today, delivered represent showed very change Vimseltinib And proud shared opportunity data across the both shows patients we we TGCT and favorable studies the they physicians treated. results a and

NDA as quickly highest look engaging quarter an of to Officer. Martin, in the MAA continues as be we opportunity, getting submit turn the of Our Chief the in regulatory call patients to and Dan Dan? priority third I'll as possible, Vimseltinib an XXXX.Now FDA forward over to TGCT to authorities work EMA with our the Vimseltinib to the to market quarter to Commercial to XXXX the second and we discuss

the MOTION standard outstanding and the to Vimseltinib in X/X potential offer Matt.Given a of believe from Phase best-in-class the study, Thanks, we the TGCT. that profile to has change and care data

on are based prevalent the opportunity. and working go-to-market our market well U.S., underway, many recently in preparations are are treated cases, These who on approximately launch disease. approved called we an we been journey and strategies systemic same and engaging our on the QINLOCK. over be patients for focus hone for the will have incident with years with our treatment patients oncologists we in engaged to patient TGCT at of understanding their the actively and seeking X and oncologist. And with options have X,XXX therapy, have X,XXX were launch diagnosed Our deep If importantly, launched since

key TGCT seeing which a at incident conservative patients overlap and In who We may a degree including the potential given duration to believe multiple based relationships patients high commercial fact, are of established the with prescribers highly advantages, U.S. treat launch. with ability capital-efficient total the in therapy. with GIST. longer be on and this estimate for offers footprint XX% XX% there's overlap market between oncologists the We $XXX those who million to X,XXX the opportunity alone, addressable leverage patients approximately

in and opportunity, results their Beyond TGCT. as administration new can limited longer the X,XXX EU, oncologist this XX no burden and/or and MOTION of Vimseltinib This market care Based had where yet core TKI-treated TKI. approximately TGCT.Our with approximately our we for a are U.S. diagnosed of the the efficacy, become These used In of picture receiving patients in significant therapy is In more almost product paint Vimseltinib only of pexidartinib and how the hepatotoxicity. impact last polypharmacy and received Patients duration our when to for blinded X,XXX low patients that was who expect months. imatinib, compelling, have Conversely, average, believe claims best about patients their and engaged of than all of received off-label but where response, year, as our patients analysis, well XX aspects not on and and steroid systemic presented combination receiving a of patients commonly incident there no the opportunity the therapy oncologists research profile longitudinal approved prevalent we the safety of see despite epidemiology efficacy we receive incident to represented these tumor much palliate a clear on includes is treated. XX% our of months. analysis additional data research study, comparable pexidartinib, morbidity. therapy patient-reported has significant significantly of patients who as imatinib. market manage and an on having opportunity. patients pexidartinib the are multiple treatment and data including data disease consistently Vimseltinib cholestatic on Grade X/X disease therapies the these of compared based offering helped rated the of X/X AEs and profile the half incidence to of to are extensive incident highly pain pexidartinib Responses medications approximately of show Phase evidence prescription treated cited standard outcomes,

Now these bring extremely attributes, of the to help QINLOCK. pending product that to approval.Turning the positive in benefits to results Vimseltinib we MOTION are excited validate strongly patients need

this a mentioned, net Steve and XX% growth As million, U.S., quarter-over-quarter. This $XX.X revenue and which XX% well year-over-year saw strong patient of In as XX% quarter-over-quarter we as includes increase year-over-year was increase another the average new product U.S., quarter. Global increase. a therapy. new yet in $XX.X million in record the increase representing is was acquisition and prescriber QX again XX% increasing duration a

the fourth at commercial extremely setting. of continued has line execute to care standard Our and level, in an high team clear the QINLOCK remains

GIST exons data ongoing INSIGHT compelling XX or XX demand supporting therapy KIT impacted of believe has unpromoted of addition, the a presented as an XX. we study earlier recent January patients lines we use in of physician with positively year, mutations ctDNA In this in pivotal Phase by from growth that INTRIGUE decision. in Recall increase been study in X result of analysis and second-line the in the

sunitinib. second-line NCCN a listed as are intolerant the March, in Additionally, who for option of treatment QINLOCK patients

we we last opportunities eager providing future revenue to progress have build opportunity.I Margarida quarters. upon now by potential these following team with the the it off-label of we International, we commercial that outlined Duarte, these right we the look on of will uses, X and results the $X greater to forward global on trends our commercial the on in and X not to have to turn Margarida? contributed commercial calls.We updates to QINLOCK factors to we and the call in We And discuss are exciting seen that over our do we growth continued Vimseltinib encouraged Together, exceed believe While detail. have believe have promote capitalize to are billion global this today. in QINLOCK revenue. the call Head Vimseltinib have over place peak the believe strong

in momentum the third XX% by sales Thanks, revenue over increase was very Dan.We remain International our of the launch product European $X.X active the in quarter. XXXX. a by $X.X identified third quarter million, net pleased QINLOCK million

innovation revenue, million the benefit concert received Italian markets. new Lab, Italy, open GIST and from European generated Zai as Additionally, $X.X revenue launched fund, expand and significantly this in innovation the am rating is is possible to care underscoring the including quarter, X we QINLOCK supply of Germany international in for Europe's for in strategy, shortened ASMR additional funded has China. treatment. end with by recognition regions. status of be the At QINLOCK.I a our Full existing team which to I successfully the royalties another unanimous share example which centralized QINLOCK of yet commitment of fourth-line establish noncurative French recognizing to ongoing of in QINLOCK seeks largest launch a multiple reserved from our the and partner for thrilled am QINLOCK QINLOCK last major received standard time continue authority, highest proud collaboration a in that innovative national in lines in In authority the treatment allows markets healthcare reach the value access work to exceptional in and rating QINLOCK of to of an QINLOCK we important the Italy, the as our full ones.

data I for KIT world, patients, to the call us back China presenting Turning strength of this recommendation see of updated we updates over the global company. Steve. mean Category released, to today's were it QINLOCK the in recognition. all and the on and clinical exciting pleased the for setting its walk To what exon our in line now were of will that guidelines listed through in future turn emphasizing now is XX XA to as second rest fiscal a the of

access potentially each operator, IND to and With improve the we'll the that, for cancer DCC-XXXX value use Margarida.Deciphera to continues deliver expand commercial QINLOCK And multiproduct pivotal medicines programs. stronger to unequivocal our the second-line Q&A. people as very we all data study Vimseltinib, in been of success our study. the to QINLOCK on steadfast discovery, drug from a out the the now strategic we with in have pursue has a momentum call of a Thank X for MOTION performance impressive open priorities to commercial to to lives ranging later around ended we never strong critical a important position. development provided deliver Phase the based say growth potential strong a INSIGHT from scale for map submit with third a and of our development world candidate our into clinical a discovery new and and in in expect that the continued an broader programs and mass. achieving path meaningful our we accomplishing now are proud million of these to nominations to of you, QINLOCK I'm close equivalents, become of commercial catalyst-rich We financial for expected laid the and our platform. stage XXXX, approximately across are road now on unchanged, we to of company preclinical remains $XXX beginning runway quarter with shareholders. of commitment the XXXX.Today's for in this goals new our and capping We to pipeline a as and quarter, with results the remain been year cash what At cash year Vimseltinib for GIST in cash cash can milestones, guidance position exciting the create company. FDA the latest proprietary has

[Operator with Instructions] first Tyler question coming the Van Buren line of Our from Cowen. TD

on you. data or in a every I have the exceeding for updates. couple Congratulations meeting themselves mark

TURALIO could rate long-term So XX% response response than overall pivotal XX overall X treatment that there and discuss can then the difference [ and long-term the outlined. showed?And X the at ] your Phase But is that between is the of week well rate rate patient the response Phase compare and was first or update, to rate population Phase that pex's delta? Phase one, that regarding a you X/X the observed above better explains the and XX% the second XX%. confidence reach But in response great you pex median XX- X-month the question pex imatinib observed duration is with as X the and XX-month that

Steve. it's Tyler, in great for the We'll questions. Thanks turn. take those

First, with of absolutely a results. XD a as a as of for see score. as placebo we you may looks and MOTION the in endpoint key first is we could testing compelling the And call, actually measurement noted tumor what you endpoints in the volume tumor volume suggests, respect response a be a secondary tumor the point, primary better X hierarchical fact, like rate of to the secondary with X the versus the patient's which recall, response of was important already, believe response significance. have as shrinkage. measurement the and name by rate indicator this, XX% endpoint better for the with study, said to delighted will we're on very statistical end other And

was now placebo. XX% So that for versus X%

results evolving with potentially pex study that So see reported we X/X Matt the on greater and this we've been how longer the on really seen what's with today. data view we're and can excited the maturity. comment based Phase with

Tyler, it's Matt.

really consistency and the patients function. of with the So these in all and and are endpoints results to secondary we secondary share data the primary that to endpoints yes, both today the endpoint how the were all able that key across feel thrilled we really speak

of from with XX%. cut. to that XX% objective the as data we've But referenced the we've expectation response our rate to increased week can the over regard initial response in as latest And XX that's study, time. Phase was today, So the Cohort rate X/X reported objective increase the A

point MOTION as starting our the So expectation well. of XX%, that have we with will increase

As XX%, you and only say, week response their response for XX they increased ENLIVEN overall rate objective had to best XX%. as well, of

now better to a that importantly, and already in we've a we'll well. XX, had feel and to point over we're And so TBS XX%. rate was the continue week continue lower we be comparison, score, data the best that week at score volume XX, volume starting at we tumor able tumor their MOTION somewhat response Cohort at a study, have evaluate as then so time. ENLIVEN XX% exceeded So disclose and in we'll overall response the XX%, for and follow A, too, At to that

response where at best nearly we're the So the analysis. pooled in they were

expectation over these grade in high that rates potential time patients. have response we again, So Vimseltinib's improve to continues

And second then, as in that question do want duration Phase to Tyler, well, X/X, the on related Matt? to comment you

that's Phase And dose really X were function of earlier. cohorts enrolled Yes. escalate a

median referenced that So longer A they Cohort so the is we months. study of Cohort X-month were enrolled the XX.X actually still duration very and function there delta have to period they now A a more just That on longer, is you for of follow didn't The a catching much up, of study. treatment XX% on of in patients that time.

to can we duration cut data patients in a future. those longer when to another treatment So continue have contribute the

in remember, the patient the that's that may that in A treated population Tyler, MOTION you Cohort we've study. same as And X, the Phase

indication, could as what So be good median could look we matures, of ultimately a of the think duration that like. really treatment data

Eun from And Jefferies. Yang coming question our next with

Congrats Phase X on the success.

physicians quite useful So in that in be usage could neoadjuvant-adjuvant from settings. we hear TGCT, its

QINLOCK. those is question are you for I'm So wondering planning second trials? And if on

it's by helped second-line quarter uptake in strong sounds sales, like usage. So third

going here? are and continue in off-label second-line increase you to forward expecting from So use

lines off-label physician to question and cover on I'll then the earlier use first trends treatment potential and your Dan off to question take related Martin for of by QINLOCK decision. unpromoted ask in

development the setting But it course, TGCT. you're is not updating certainly superior be theoretical changes, an we've like setting would We development might investors additional in disease inhibitor with extent in even and then setting on in to might a first, announced Vimseltinib our or that surgery, to surgically with on able like in ongoing earlier of will, go perhaps be to line they the resected pursue Vimseltinib this been in have have clinical neoadjuvant there earlier able program, on whereas result role basis. adjuvant we before an respect that for to in right, be Eun, to where Dan? So perhaps be work drug treated don't a to plans outcomes. surgical plans certainly, first potentially patients an Vimseltinib an or

year-over-year are the really in about a over notable last we in and year-over-year quarter-over-quarter growth and really in growth we was the XX% QX. quarters that on the and QX It's XX% of couple XX% performance U.S. XX% now of So top excited to what in then quarter-over-quarter the growth QX strong saw see very the particular.

we and continuing we of clear an mutational XX and in the profile course, be of we treatment had we do ctDNA execute As outstanding this with number for provided factors result call, impact, NCCN sunitinib, a but patients exon noted, job a team benefit meaningful strength and be on X in see XX patients both the second-line noted have believe then to in places. continues these specific And showing and in think The that the intolerant we do or can we noted, done that to off-label listing has a these any don't the a of fourth-line. may XX promote of that standard being dramatic as the analysis for setting. we who uses, setting the in

look that not or whether expectation, as ahead, we seen we've trend say our hard of it's the to terms continue. will In

monitor We to will continue it.

this really just with arsenal see highly most get of recent as I really for a think pleased patients their part reflection of the continue dynamic from how treatment feedback overall, with we QINLOCK and value is GIST. to we be physicians physicians continuing

Guggenheim. And line with Schmidt question from the our coming Michael of next

know as about about to talked that of I which secondary the has pexidartinib positive think me. you well, for differentiation particular before, of I endpoints as outcome those outcome expectation? trial perhaps you've Congrats important QOL,in the And some to your well efficacy. increase matched relative that most on on are talked outcomes with

want you Quick the Yes. that? do endpoints. Matt, take to question Michael. Thanks, on secondary

it's Matt. Michael, Yes.

we thrilled, yes, points. So the end are all secondary course, with of

the important itself in how shows they highlighted criteria more tumor patients. score used I we is aspect standard TGCT actually, that the the even compared value one tumor RECIST today a they that think, contribute of will that We of So really tumor expect because to for together, responding is the to initially Vimseltinib volume measurement.

a shape solid Of having the to tumors, volume more tumors to was so that irregular course, spherical first compared developed of TGCT very RECIST shape for join.

shrink, score computer-assisted importantly, how feel highlighted is the measures as trial. of X patients. missing endpoints, tumor quantification And to quality very of secondary key really that PRO other the for function. they of So improve showing a of measurement a motion only of of life treatment. that The outcome to developed a life measures because way previously, think, Vimseltinib their of ENLIVEN therapies range the the important other was the that pexidartinib responding how collection and in had really a including of But important TBS patients has is aspect data tumor the limitation change of life that And and of quality volume. just and that is in now, more patient-reported but the also not been quality lot in their Phase we've I differentiating

So having the to range label only limited motion they pexidartinib. in for of are U.S.

the So our share and a of forward of FDA we with submitting just some the including opportunity NDA for thought leaders the to we all And the to to outcome these had to measures. moment, over investigators. weekend the share results look and key

that Vimseltinib. is the of not the positive to contribute back secondary just it's how endpoints it's and the and a about about feel few really And that function tumor, but comments results will words, use all extremely some just of to success outstanding came of feel patients transformative and that the

talked patients, there Great. other this presurgery opportunities X,XXX about or in now you about label in an now hand, real is And you with I the expansion incident any the result in the hand? then think some patients prevalent could perhaps earlier-stage potential data for know But of quick in U.S. with evaluation and X,XXX patients additional the opportunity

theoretical announcement with the and we're respect with a on really drug today has a study, We question earlier, a explore been an or neoadjuvant of where of figured in for additional I until the Eun's think treatment setting opportunity now, the places don't a which could is broadly we like kind I surgery? but of I other back there have certainly possibility. think this potential up Vimseltinib diseases. or the it So to a more in disease running whether that TGCT remains the care be certainly role standard is patients, that role with adjuvant such the evaluating to benefit

the next line Piper Sandler. coming from with our Christopher And of Raymond question

Congrats from me as well on the data.

on follow-up itself QINLOCK. to to then pexidartinib, clearly safety just thinking hoping a the then chances Box, the about data are should guess, Box. labeling. box maybe the where no I you should of Just chances black a on there? a And I I advantage versus for and you're a still But how speak toxin, FDA Box the stuff. about and know have guys avoid Black And maybe a know for you thinking, we implications but how over talk have still are Black CFXR-like I communicating commercial talk data Black to the showing with you're be is the

I well But to is it the REMS Box further Black certified believe of receptor based to in Dan with their asserted the don't the to not you'll the to warning requires of between was class back to risks a made you X/X to and physicians prescribe as to is you're ODAC patients, Daiichi, the a to pexidartinib than we've And respect dispense benefits data the MOTION an Phase now that hepatotoxicity. And as remember, headwind inhibitors be have being drug, of potential which as so We with important an the subject of effect. in remember, of in certified to potentially hepatotoxicity related course, the probably physicians a and certainly terms this in there's any Black drug. and, agent pexidartinib, is on real the data risk off-target CSFX our I cholestatic that at both and notation to as fatal we impact. own think treatment. on be study distinction to comment think course, from And other of may study. It's willing and pex effect has can reported evaluated pharmacies referring the of this with program, treatment. Box case REMS we And been program. been commercial see be the other go imagine the other XXXX, patients well of the be informed potential

the view we'll of FDA. add the our I would that's that, with of engage So landscape. just course,

data, We years. out where X the have Phase we Matt database. treatment patient the is have outlined longest X/X robust to a now updated on

So as we longer-term Phase of from have the which safety communicate the we benefit a to with follow-up the X/X helps but by experience, very long-term think efficacy the use. drug also drug measured of broad the

then And Great. maybe on maybe. QINLOCK,

obviously, into of kind is my first to first sort from plan big as is language, perspective just your reset going a use full NCCN account on taking of thing. sense payer So it's and be plans the XXXX the a in comments second-line full year year with

a thinking to dynamics got but that issue, this about. I a Just you'd be payer expect? any about that any could know that think promotion policy second-line you've obviously, Should planned changes about we maybe in dynamic tailwind talk a not setting? is be payer

question. Good

for the and access payers unmet broadly The patients the tool is as to meaningful So change broad barriers provides we since of really earlier relates in QINLOCK. any quite the the anticipate how expect and product of use. to seen But quite dynamic be the really expect for any don't need would to launch, changes. is reflection we that there profile. payer if fact a is intolerant We them beginning that any to of be meaningful certainly We've engage line who a discretion access with listing it which payer may and to physician there outstanding were continue. to clear open NCCN just sunitinib, strong candidly payer significant don't

the from Berens our next And Leerink line coming Andrew of question Partners with

Just for a getting more. or results me. it the X/X like years patients good for Based sounds Phase trial, at X are least on couple most

the get? Are getting or GvHD. they class And CSFXR them off agent? drop of another number they moving what of sets have in patients that surgery data a are to then activity Just has wondering shown treatment

lastly, And if guidance, Just rare some us results could the obviously, now but just you launch? addressable disease-type it's how to have is think wondering official Is early TGCT. on and frame existing that you overall wondering going then this ramp. from could drugs give market, this quickly likely color or a if for adoption rapid you a a you consideration then from since the switching more be

It's Steve.

So is following proof the which antibody. the generated looks let CSFX course, receptor been competitor treatment in me take concept GvHD. mechanistic a that's data of We have first chronic your second compelling an of and quite showing GvHD, clearly now that with space closely using the about program question certainly disease. That, for of inhibitor

backdrop We have used oral agent of the are that benefit obvious other an of the being agents against and oral GvHD. to being treat

So that evaluating. very actively is a we're space that

really and evaluated MOTION announcement especially a and now no with So for path, to that's patients TGCT. strikingly get results, context we study of to something believe, actively today, have in being market it's them positive we the but clear

for to other Vim expectations talk comment be treatment able patients. places first Vimseltinib. about the I'll flip where Matt can subsequent may incumbent and launch on Dan it question benefit to about it's upon Now over Matt? then evaluate us the to to

Andy.

we living value that certainly period So reason Interestingly, I to why unresectable within and these may some come surgically some treatment. have Vimseltinib, single a nonamenable reasons trial could to to patient the gone there come Europe. or stopped. earlier, be mentioned that in prior enrolled one as also One to And hasn't was a patients patients who think who X but that patients working the speaks into had off was younger surgery. there in least are following treatment, initially trial on decision other have are these who's they therapy. patients off potentially they the were during at who we've with have had who resectable families patients Also been

and re-enrolled remained the back a back who able we on previously treatment the that He the CSFX actually of back then study when and Phase the has a study. patient patient was receptor had and wanted have reasons, He and in was trial. onto went that but on inhibitor, B Cohort patient A, patient escalating continues enrolled in treated good study well also a had from as to work discontinued discontinue, previous the a for came Vimseltinib. trial, had come treatment he has very second previous part So the on the trial. was treatment as on then, to And a to in X later response and And as then on re-enroll, the well, Cohort he since too.

that for in the So with use retreatment commercial actually to the very speaks possibility Vimseltinib, excellent setting.

take I'll Yes. on the anticipate. dynamics we launch that last question Vim of sort the

But told for importantly, looks us, the that's they demonstrated a tolerability continually more pexidartinib safety as on say definitely that that to a expectations. inhibitor. It looks like that early we still a be this is to certainly validated it's But can what closer more efficacy have profile We'll with like with they much get for our by has as that think MOTION both profile that's say the CSFXR a launch have example. potent that and of have a color extensive we level would want is best now imatinib, worlds. giving like us to physicians bit I launch. comfort

are considerable think that is a And the so that think we actively -- strength of cases, for many or we systemic their talked it therapies relates profile, we in that disease options about, pursuing given these at treatment in today. really, core there that, practices profile, receiving on opportunity diagnosed, to launch oncology patients that as think those we best-in-class they're the we call

is as peri-launch not overall keep So rare you to sort and opportunity we of diffusely core disease real that that additionally, there's a considerable sort is distributed of think GIST. mind there. in this And important unlike it noted,

TGCT of profile more especially be an not that broadly, And the pexidartinib there active experience had will of because as so that those the that REMS opportunity in educate have and physicians program. much to means the limitations

a is opportunity growth And think so well. as that time we over

layers really and viewing potential forward opportunity we're in multiple launch. So to looking the there a

coming Bradley the line Canino with Stifel. And from question our next of

[ for Bjorn ] the quarter. Brad And Two this in is on questions. data on positive Congratulations Canino. the

EU on is is Vimseltinib. first regulatory The around pathway. question the Largest

a what was EMA negative collection a pexidartinib? benefit to Vimseltinib? you than also, or and the on CSFXR As that was the of you benefit benefit you've [indiscernible] you know, think risk TURALIO's risk negative less for profile within confidence region. assessment conduct inhibitor for data the better in that Do gives this was And collected a trial prior in projection EMA

I'll take the question.

right. So you're exactly

the the Daiichi's based we way with data of a Europe to Europe, know for level understanding cholestatic also negative the EMA I the was regulators, characterize to measured a think, understand benefit to more hepatotoxicity. on of HCA EMA drug contributed the by profile outcomes. which important missingness population discussion the as that driven impact broadly more on in risk think patient by probably And that secondary are I in endpoints, patient in to approach was a that both certainly I by bodies reported rejection principally pex. think our is you And poor

range measures whether secondary the that pain, quality reported X endpoints view measured So motion have whether the information drug been of of we, course, we patient has have that's pexidartinib. issue And of with is it's reported life hepatotoxicity and really data outcomes, physical and our neither cholestatic positive measures. exceptional of the we key in function the all other by have or bolstering case, of from

package the So compelling. we quite think is data

outcome the the Europe. but over number group a EMA as drug, of evaluate about and sarcoma safety that efficacy And thought that Matt of included alluded And leaders members we to steering and how were from the engage remarked speak and the package measuring investigators home of in we just than Vimseltinib had they leaders with opportunity the investigators of we'll a improve Europe. were point program. outcomes patient we has add the that on was other development profile that, driving the data for review patient-reported compelling also with data, and how top just for Vimseltinib the drug thought committee potential course, as as the the in excited tumor the Of with I'll that how to weekend, had treatment potential to FDA, the compelling shrinkage. number importantly, the

helpful same So data we hear. the found in And that way. to package EMA that the really believe to view will be the we

And helpful. some we're peak quarter from QINLOCK. sales QINLOCK? second-line. on for one need just Very to your then consider seeing is contribution more the What first This you of see disclosure do broadening target to

part last there. to, need the see your last do the of question, bit missed So I to on what we

broadening target for consider disclosure To peak for sales your QINLOCK.

you take the would to Dan, question? like

absolutely. sure, Yes,

a Bjorn [ So of thoughts couple ]. there,

could peak think the terms as has double think revenue that U.S. of communicated for We've we to we INSIGHT really up alone. $XXX changer in potential the the of it study the the in the million So to to sort communicated peak U.S. we in that us opportunity upwards game this sales the be the for ultimate franchise of point,

response will I hard that a the relates trend we'll on on seen dynamic we've last That's I unpromoted or that remain recent think impact that as earlier use. from It's couple as dynamic that see and the the how goes. my it question, to to earlier have mentioned not. line that quarters an just whether predict over to of

monitor we so we'll like. color think could have we just to what future the that additional to as as and And provide look go

Reni question with the next from Our coming Benjamin line Securities. JMP

Maybe results. great couple a for these me. just on Congratulations

probably this priority Andy's just perspective? you As pexidartinib was prepared of just. that think since this questions. does up, upon from think the you the advantage XX% launch Or so FDA we as a actually following And that do your it comments, look think review the a sales or launch? and of to is marketing like effort or full of I about And and the approved we force with sales But kind guess opportunity, that I might the shortly overlap force, about think already will full what after be I existing know taking rightsizing be review? in XX% the mentioned

do will utilize be physicians As these initial about place would Vimseltinib? patients that you going sort are ideal patients Will will think Vimseltinib, think be of they you that Who the imatinib, the naive patients? patients? be post-pex post on to

the for is X Steve. good Thanks questions. This

we sure adding take the review comment the vimseltinib Dan as to to force priority let and Margarida, implications about also initial U.S. we question sales ask I'm then then can on me I'll add the First, you and potential be think launch bag, Dan on and and being initial with will, about comment opportunity which targets, dynamic think patients if can for the treated sorts and of vimseltinib. how for might

So ], to Ren question, it's priority on [ early too us the review for know.

priority engage pre perhaps to or be FDA considered will time Of course, our with and that at we'll whether meeting, the understanding not the drug better a for we'll in have review. as

reviewed may under pex you priority As remember, review. was

option. FDA, on engaging So want forward look to comment that's an we'll first data you but on as view encouraging Margarida, and European as the point, that we to be a with answer Dan exploring the certainly take U.S. portfolio an adding then that to into force the question the uptake with see then deployment follow you in and in how of Vimseltinib same related terms can sales and and do

to. Happy Sure.

to high team determined the the lean and consistent is plan with targeting in infrastructure, believe a overlap will focused our raising we demand European U.S., currently So Vimseltinib. there deploy QINLOCK, a so consistent is for we and that optimized for awareness cost with generating are customer-facing also physicians that with be the

in we So plan believe exists overlap this Europe. of continue to to advantage the we and high also also will thinking that according taking

informative our I that that that that opportunity. data So data identified it's that is market U.S. important the summary journey incident really really And a patients bringing the or ways. claims deeper because ways into really X,XXX to really think your direct slides in a few deck, able largely U.S. of we that corporate I based in think together both that core number prevalent understanding that speak to being on and to you parts the in These and the of much opportunity, in number we and to latest X,XXX as analysis, patient think way outline a approach our go we and primary we most actually of I recent question. put the in-house the

therapies they've engaged these are with with an So diagnosed. systemic treated oncologist They're and importantly, are who patients recently. really

well. know that means that that the engaging So they with they're we actively for treatment are disease, and also pursuing very options oncologists their

it From really there. force to sales us important a of approach. enables so couple implications a capital take expansion a And efficient perspective,

a to addition, strong that be advantage So incremental of other we a core addition we'll with in are able would We the not target certainly, thing of the in opportunity newly burden X,XXX And is that anticipate clear that we dramatic U.S. receiving lion's and order those manage steroid really patients take way. their to We outlines we TKI are would TKI believe incident an patients for synergy.I medications. patients patients about pain in take this disease. that to patients we to and were be what able receive of patients today. certainly And purpose. the today. able a identified, getting see to just be to us, polypharmacy the these really And agent way, that, But see receiving significant patients. that take the the think those would beyond of treated the just that any for best-in-class half share capture these other

systemically will to without manage disease. these it's think drug the to we palliate What underlying tended continue treats as engaging profile actually better those of to penetrate AE of has that that oncologists. willing to well. cause. with a on patient their this concerns about their on largely They're option, they're And the population burden drugs that patients going be with a be we pexidartinib So the that able disease hear really to we is

we So changer for patients think Vimseltinib that will those a well. game as real offer there

we types, will for be think, launch. at both So us opportunities key

Instructions] And next coming Barclays. the Lawson line [Operator our with from question Peter of

on the on data call. the Congrats

quantifying of about Is we How should you've puts level all data? ones? that thinking any to XQ? XX%. way that in Vimseltinib, And U.S. of the kind TVS that of compare takes the then And seen quarter? and off-label use be prior Just any the of driving score on does

that take use And the in your the study then MOTION take on in about what to in question I'll question unpromoted Dan off-label the can ask and quantify U.S. to terms for of TVS what and trying also saw then Matt is. we Phase X/X TVS.

Dan. it's Peter, Yes.

core really been and that the that. setting couple that yes, really critical last We've big to our X last line noted over is part of fourth of growth success really, So the I've see really strong over excited our the quarters. results. has continued to quarters execution in been a

well course, in seen trend it this and use of through flowing new forward. relates continued to average We future. line have terms stable business is recent a this acquisition we to of sort patient of relatively we, as believe have fourth out exactly significant change volume to a driving which. part to therapy definitely we over trend. increasing a of we the in break are that But couple of earlier amount that fact bottles But course, of the as have long line quarters. gradually in hard, both history course, there's before, It's important given last on we what to as think trend of and the be yes, parse see, a then, of moving have may is demand noted the what an as growth which in duration that as now evidence considerable the anecdotal of of we've impact

feel All a earlier over this from significant together, the that quarters increase portion taken couple confident unpromoted line use. that of of we come last has of the

increase X/X a this the longer-term tumor data a noted, with we in used week is at when A we the is we And computer-assisted XX% now as tumor population XX% the we've Cohort study, volume. quantification XX did that the Peter, score today from follow-up. of volume a Phase response as the had TVS updated

we time that as at actually earlier, is followed So at study, Vimseltinib as mentioned TVS in the go well. and in this with Motion will be similar, up MOTION And be expect this a had to will treated XX%. XX higher continue we week arm over the response

to Got And think pexidartinib as about do of of expect of you. in the pex off And Vim, patients switch then U.S. beginning? what's kind current maybe we your off on U.S.? in estimate use of the physicians use TGCT, you

appreciate Thanks, I Yes. the it's question. again. Dan

data from the patients, And take that XX%, this claims call that the has shown TKI. initiated on XXXX of slides, pexidartinib. about those analysis treatment you the data of our XX% incident if out a of patients XX% we X,XXX in initiated on those is So

other other the receiving what minority to of the imatinib. was certainly, your most received trying the there, I'm the remember part TKI question? of patients So

imatinib... either from Switching Yes.

that we certainly think the potential So switching. there is some for

data, do have there's minds, that Now weighing on their demonstrated that patients doing efficacy, for these it the market to agent questions. understand do we'll that that potential when be But tell we MOTION has profile. fact given the receive always of side research us think benefits switching and a the even they effect given we additional best-in-class good from it's pexidartinib types

come So issues including, that whitening. are hepatotoxicity We these with this other of frankly, hair population. pexidartinib, all patient that from the to and patients challenges dynamics hear

these on patients. those minds of so of always sort weigh the And

So we given best-in-class potential we have agent, some will the switches. opportunity think the for and that given

Eun have a with Yang question And we Jefferies. from follow-up

questions. quick Two

For second-line second-line R&D, sunitinib? MOTION running Tucker second patients to is intolerant to are considered question are percent the the but GIST, trials you and trial what others. of with And for ended, GIST

quarter So the rate that how be run to be rate going for Will do run you XXXX? expect number go R&D to from forward? third

Dan will on take sunitinib intolerance the [indiscernible] Tucker. question

to overall, to others. of tend may second-line it relates So in we patients what who patients, NCCN physicians some as But of sunitinib. some intolerance higher varies What XX% be percentage of a to this range we have intolerant than somewhere in to the cite some to hear hear may is degree, XX% relates the sunitinib. March listing for physicians patients from course,

and physicians recent has these the in Tucker? contributed for consideration And meaningful something as a increase that, to is that that, think demand noted, volume. we we So

question thanks expenses. the the for on R&D Yes,

we're forward higher range that So be similar would little the as a the but clinical R&D obviously going then to don't modest depending expenses guidance, trial getting on provide we well. launch OpEx with on would a quarter. Vim as just CMC in increase INSIGHT got the we obviously bit a running We've well And ongoing up for and studies. QINLOCK, material as expect the than

more some that, expect increases, to time. we would be modest come ones could but but over significant on So

And questions at you. closing over remarks. I Hoerter call will now Mr. in back to I any further this time. Thank see no the for Steven turn the queue

on our you you you of and very a much. your Thanks great call. Thank day Hope joining forward keeping everyone for progress updated Great. Deciphera. ahead. at here us you Thank rest to great have to We on look week for continued your today's support. a

gentlemen, and participation. for Thank our today. conference does that for for your Ladies you

You may now disconnect.